|
|
||||||||
Papers In Press, published online ahead of print August 10, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679
Corresponding Author: bvanlent{at}mednet.ucla.edu
Rabbits on a 1% cholesterol diet received injections of vehicle with or without D-4F or L-4F. After 1 month the percent of aorta with atherosclerotic lesions was 24 ± 15% (vehicle), 10 ± 6% (D-4F) (p<0.01 versus vehicle), and 13 ± 9% (L-4F) (p<0.05 versus vehicle). Inflammatory indexes for HDL and LDL were determined by measuring monocyte chemotactic activity after adding rabbit lipoproteins to human endothelial cells. HDL-inflammatory index (HII) and LDL-inflammatory index (LII), respectively, were 1.39 ± 0.24; 1.35 ± 0.29 (vehicle), 0.67 ± 0.26; 0.63 ± 0.38 (D-4F) (p<0.001 versus vehicle), and 0.67 ± 0.2; 0.68 ± 0.32 (L-4F) (p<0.01 versus vehicle). Serum amyloid A (SAA) levels were 95 ± 39, 8 ± 22, and 7 ± 19 µg/mL, respectively, for vehicle, D-4F, and L-4F (p <0.001 versus vehicle). There was no correlation between lesion area and total plasma or HDL-cholesterol levels. In contrast, there was a positive correlation with HII, LII, and SAA (p = 0.002, p = 0.0026, p = 0.0079, respectively). HII correlated closely with SAA levels (r =0.6616; r2 =0.4377, p<0.0001). Thus, HII, LII and SAA are better predictors of lesion area than total plasma or HDL-cholesterol levels in cholesterol-fed rabbits.
Revised on August 7, 2007
Accepted on August 9, 2007
Lipoprotein inflammatory properties and serum amyloid a levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Peterson, G. Drummond, D. H. Kim, M. Li, A. L. Kruger, S. Ikehara, and N. G. Abraham L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice J. Lipid Res., August 1, 2008; 49(8): 1658 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J. Lipid Res., June 1, 2008; 49(6): 1344 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Subramanian, C. Y. Han, T. Chiba, T. S. McMillen, S. A. Wang, A. Haw III, E. A. Kirk, K. D. O'Brien, and A. Chait Dietary Cholesterol Worsens Adipose Tissue Macrophage Accumulation and Atherosclerosis in Obese LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 685 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |